

AMENDMENTS TO THE SPECIFICATION

Beginning on a new page immediately before the claims, please replace the existing sequence listing with the attached substitute sequence listing. Please renumber subsequent pages accordingly.

Please replace the paragraph [0184] on page 57 with the following amended paragraph:

[0184] Table 5: Sequences of *Cis*-repressive RNA Sequences, Loop, RBS, and crRNA Constructs. All sequences are shown 5' to 3' and represented in the form of their corresponding DNA sequences as used in the cloning steps.

| <i>Cis</i> -Repressive Sequence | Sequence ID NO: |
|--|--|
| C GGACGCACTGACCGAATTC | SEQ ID NO: 3 |
| crRL CTACCTTTCTCCTCTTTAAT | SEQ ID NO: 4 |
| crRB TTCTCTAGTCCTCCTTAT | SEQ ID NO: 5 |
| crR7 CTACCTTTCTCCTCTAGGA | SEQ ID NO: 6 |
| crR10 CTACCTATCTGCTCTTGAA | SEQ ID NO: 7 |
| crR12 CTACCATTACCTCTTGGA | SEQ ID NO: 8 |
| crR22 CTACCATTACCTGGA | SEQ ID NO: 9 |
| Loop TTTGGGT | SEQ ID NO: 10 |
| RBS ATTAAAGAGGAGAAA | SEQ ID NO: [[11]] <u>10</u> |
| Sequence of <i>Cis</i> -Repressive RNA Constructs | |
| C GGACGCACTGACCGAATTCATTAAAGAGGAGAAA GGTACCATG | SEQ ID NO: [[12]] <u>11</u> |
| crRL CTACCTTTCTCCTCTTTAATTTTGGGTATTAAAGAG GAGAAAGGTACCATG | SEQ ID NO: [[13]] <u>12</u> |
| crRB CTCTAGTCCTCCTTATTTTGGGTATTAAAGAGGAG AAAGGTACCATG | SEQ ID NO: [[14]] <u>13</u> |
| crR7 CTACCTTTCTCCTCTAGGATTTGGGTATTAAAGAG GAGAAAGGTACCATG | SEQ ID NO: [[15]] <u>14</u> |
| crR10 CTACCTATCTGCTCTTGAATTTGGGTATTAAAGAG GAGAAAGGTACCATG | SEQ ID NO: [[16]] <u>15</u> |
| crR12 CTACCATTACCTCTTGATTTGGGTATTAAAGAG GAGAAAGGTACCATG | SEQ ID NO: [[17]] <u>16</u> |
| crR22 <u>crR22</u> CTACCATTACCTCTTGATTTGGGTATTAAAGAG GAGAAAGGTACCATG | SEQ ID NO: [[18]] <u>17</u> |

Please replace the paragraph [0194] on page 60 with the following amended paragraph:

[0194] Table 6: Sequences of *Trans*-activating RNA Constructs. 5'-st represents the 5' stabilizer element inserted in front of taR12. All sequences are shown 5' to 3' and represented in the form of their corresponding DNA sequences as used in the cloning steps.

| Construct/Sequence | Sequence ID NO |
|--|--------------------------------|
| taRL ACACCCAAATTAAAGAGGAGAAAGGTAGTGGTGGTTAATGAAA-ATTAAGTTACTACTACCTTTTCTTAGA | SEQ ID NO: [[19]] <u>18</u> |
| taRB ACGCCCAATAAGGAGGATAGAGTGGTGGTTAATGAAAATTAAC-TTACTACTTAGTTTCTTAGA | SEQ ID NO: [[20]] <u>19</u> |
| taR7 ACACCCAAATCCTAGGGAGAAATGGTAGTGGTGGTTAATGAAAA-TTAACTTACTACTACTTTTTCATAGA | SEQ ID NO: [[21]] <u>20</u> |
| taR10 ACACCCAAATTATGAGCAGATTGGTAGTGGTGGTTAATGAAAA-TTAACTTACTACTACTTTTCTTAGA | SEQ ID NO: [[22]] <u>21</u> |
| taR12 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT-TAACTTACTACTACCATATATCTCTAGA | SEQ ID NO: [[23]] <u>22</u> |
| taR12A ACCCAAATCCAGGAGGTGAATGGTAGTGGTGGTTAATGAAAAT-TAACTTACTACTACCATATATCTCTAGA | SEQ ID NO: [[24]] <u>23</u> |
| taR12B ACCCAAATCCAAGAGGTGATTGGTAGTGGTGGTTAATGAAAAT-TAACTTACTACTACCATATATCTCTAGA | SEQ ID NO: [[25]] <u>24</u> |
| taR12C ACCCAAATCCAAAGAGGTGAATGGTAAGTGGGTGGTTAATGAA-AATTAAGTTACTACTACCATATATCTCTAAGA | SEQ ID NO: [[26]] <u>25</u> |
| taRU112 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT-TAACTTACTAAAATCGGACATCTCTAGA | SEQ ID NO: [[27]] <u>26</u> |
| taRU212 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT-TAACTTTACTACTTACGCGTCATATCTCTAGA | SEQ ID NO: [[28]] <u>27</u> |
| taRU312 ACCCAAATCCAGGAGGTGATTGGTAGTGGTGGTTAATGAAAAT-TAACTTACTACGATCAGTGATCTCTAGA | SEQ ID NO: [[29]] <u>28</u> |
| taR22 ACCCAAATCCAGGTGTATGGTAGTGGTGGTTAATGAAAATTAAC-TTACTACCATTACCTCGATCTAGA | SEQ ID NO: [[30]] <u>29</u> |
| 5'-st GGGUCCGCUAUGAGGUAAAGUGUCAUAGCGGGCCC | SEQ ID NO: [[31]] <u>30</u> |

Please replace the paragraph [0199] on page 61 with the following amended paragraph:

[0199] Step 2: Complex formation. For each of the riboregulator pairs, six samples with different molar ratios of taRNA-crRNA were prepared. The concentrations of taRNA in the six samples were: 1.0 μ M, 0.50 μ M, 0.25 μ M, 0.13 μ M, 0.06 μ M, and 0.03 μ M. The concentrations of crRNA were 0.20 μ M and 0.01 μ M for cognate (e.g., taR12-crR12) and non-cognate (e.g., taR10-crR12) pairs, respectively. Each of the samples contained 10 μ M Tris (pH=7), 10

μM MgCl₂, 1 pM KCl, 1U of RNase inhibitor (Applied BioSystems), and 0.4 pM of Cy5-labeled reverse transcription primer (5'-Cy5-CTTCACCCTCTCCACTGAC-3') (SEQ ID NO:[32] 31). The reverse transcription primer was designed to anneal the crRNA approximately 80 nucleotides downstream of the *gfpmut3b* start codon and contained the Cy-5 label at the 5' end. The samples were given 20 minutes to equilibrate at 37°C.

Please replace the paragraph [0209] on page 64 with the following amended paragraph:

[0209] Table 7: Real-competitive PCR Assay Design.

| | |
|-------------------|--|
| Assay: 16SrRNA | PCR Primer 1: 5'-ACGTTGGATGGGAGACTGCCAGTGATAAAC (SEQ ID NO: [33] 32) PCR Primer 2: 5'-ACGTTGGATGTGTAGCCCTGGTCGTAAGG (SEQ ID NO: [34] 33) Extension Primer: 5'-GAGGAAGGTGGGGATGACGT (SEQ ID NO: [36] 34) Terminator Mix: CGT Competitor Seq: 5'-TGTAGCCCTGGTCGTAAGGGCCATGATG- ACTTCACGTCATCCCCACCTTCCTCCAG- TTTATCACTGGCAGTCTCC (SEQ ID NO: [37] 35) |
| Assay: crRNA | PCR Primer 1: 5'-ACGTTGGATGGGAGAGGGTGAAGGTGATGC (SEQ ID NO: [38] 36) PCR Primer 2: 5'-ACGTTGGAAGAGGTAGTTTTCCAGTAGTGC (SEQ ID NO: [39] 37) Extension Primer: 5'-CATACGGAAAACCTACCCTT (SEQ ID NO: [40] 38) Terminator Mix: ACT Competitor Seq: 5'-TGTAGCCCTGGTCGTAAGGGCCATGATGAC- TTCACGTCATCCCCACCTTCCTCCAGTTTAT- CACTGGCAGTCTCC (SEQ ID NO: [41] 39) |
| Assay: taRNA | PCR Primer 1: 5'-ACGTTGGATGTTTCTCCATAGTCGACACCC (SEQ ID NO: [42] 40) PCR Primer 2: 5'-ACGTTGGATGCTGCCGCCAGGCATCTAGAG (SEQ ID NO: [43] 41) Extension Primer: 5'-GAAAATTAACCTACTACTACC (SEQ ID NO: [44] 42) Terminator Mix: CGT Competitor Seq: Plasmid construct taR 12 (for taR L,10) or Plasmid construct taRL (for taR 12) |

Please replace the paragraph [0211] on page 65 with the following amended paragraph:

[0211] T7 = 5'-TAATACGACTCACTATAGG-3' (SEQ ID NO: [[45]] 43). The same set of primers could be used for all crRNA variants because they all contained the same 5' and 3' ends. Due to variable 5' sequences on the taRNA constructs, unique primers were designed for each PCR amplification. The same reverse primer was used in taRNA PCR reactions.

| Construct | PCR Primer (forward) |
|--------------|--|
| crR7, 10, 12 | 5'-ATTACTCGAG-T7-TCAGCAGGACGCACTGACC (SEQ ID NO: [[46]] 44) |
| taR7 | 5'-ATTACTCGAG-T7-ACCCAAATCCTAGCGGAG (SEQ ID NO: [[47]] 45) |
| taR10 | 5'-ATTACTCGAG-T7-ACCCAAATTCATGAGCAGATTG (SEQ ID NO: [[48]] 46) |
| taR12 | 5'-ATTACTCGAG-T7-ACCCAAATCCAGGAGGTG (SEQ ID NO: [[49]] 47) |

| Construct | PCR Primer (reverse) |
|--------------|--|
| crR7, 10, 12 | 5'-GTCCAAGCTTTTATTTGTATAGTTCATCCA (SEQ ID NO: [[50]] 48) |
| taR7 | |
| taR10 | 5'-ACCACCGCGCTACTG (SEQ ID NO: [[51]] 49) |
| taR12 | |